HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Abstract
The original version of this article unfortunately contained a mistake.
AuthorsAlejandra González-Duarte, John L Berk, Dianna Quan, Michelle L Mauermann, Hartmut H Schmidt, Michael Polydefkis, Márcia Waddington-Cruz, Mitsuharu Ueda, Isabel M Conceição, Arnt V Kristen, Teresa Coelho, Cécile A Cauquil, Céline Tard, Madeline Merkel, Emre Aldinc, Jihong Chen, Marianne T Sweetser, Jing Jing Wang, David Adams
JournalJournal of neurology (J Neurol) Vol. 267 Issue 3 Pg. 713-714 (Mar 2020) ISSN: 1432-1459 [Electronic] Germany
PMID32030522 (Publication Type: Published Erratum)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: